



First topical 7-day therapy: defining a new standard of care for replacing EyeDrops and Injections.


biophta

BIOPHTA's proprietary biopolymer technology enables a transformative solution to major limitations of today's retina treatments as well as for front-of-the-eye.



	Eye Drops	Anti-VEGF Injections	Long-acting implants	BIOPHTA topical insert
Non-invasive	✓	✗	✗	✓
Sustained delivery	✗	✗	✓	✓ (7 days)
Retina treatment	✗	✓	✓	✓
Self-administration	✓	✗	✗	✓

New standard of care that offers a non-invasive, 7-day topical microdosing, to provide a continuous therapeutic exposure for replacing injections or daily eyedrops. This scalable platform offers a transformative solution to poor adherence, burden and pain of injections, as well as inconsistent outcomes.



Pipeline:


- BO-001 Glaucoma – \$6.9B market – FDA fast-track validated – Phase I 2026
- BO-002 Macular Edema (Retina) – \$4.3B market – replaces injections – R&D

Completed:

- Insert formulation & development
- GMP manufacturing & GLP trials
- €6.5M pre-Series A secured (2024)
- Significant traction from large pharma

Upcoming Milestones:

- 2026: First-in-Human (Glaucoma Phase I)
- 2027: Series A funding round
- 2027: Retina GLP studies
- 2029: Retina Phase I



Jean GARREC – Founder & CEO
e : jean.garrec@biophta.com
m : + 33 (6) 82 65 45 19



- 20+ years ophthalmology
- General management
- Global business development